Synoptics Health: ProReveal product launch update

RNS Number : 3055T

Scientific Digital Imaging Plc

12 December 2012

 



 

Scientific Digital Imaging plc

("SDI" or the "Company")

(AIM: SDI)

Synoptics Health: ProReveal product launch update

Cambridge, UK: Scientific Digital Imaging (SDI), a leader in innovative digital imaging systems for life science, technology and astronomy applications, is pleased to provide an update on its recently launched new division, Synoptics Health.

During the past six months, SDI's Synoptics Group has introduced the new division of Synoptics Health which has developed a patented system which addresses the major problem of detecting dirty surgical instruments in hospitals. The need to improve the washing processes used in hospitals world-wide is currently a hot topic since dirty instruments can result in costly hospital closures and more importantly, can lead to cross contamination of patients. The Synoptics Health ProReveal system has been launched to wide acclaim since it is a highly sensitive fluorescence-based test going far beyond the capabilities of current techniques.

The ProReveal technology has been developed in conjunction with Queen Mary University of London over the past four years and has been shown in trials at Great Ormond Street Hospital and University College London Hospital to detect nanogram levels of protein contamination on surgical instruments, which is around 100 times more sensitive than tests currently used. Using the ProReveal technology will ensure that surgical instruments are being properly checked for contamination from proteins such as prions that cause vCJD and could help reduce the number of cases of post-operative infection.

ProReveal was introduced at four major trade shows in October and November 2012 to appeal to hospital sterile services departments. The ProReveal technology was well received at the shows and orders have been placed for 10 systems in the UK since launch. In addition to the UK market, strong interest has already been received from Germany, Ireland, Malaysia, Italy and Korea. The growth in expected sales of the ProReveal product will ensure that SDI finishes 2012 with strong growth in turnover.

SDI's other divisions are also enjoying strong sales, most notably Syngene's PXi system for imaging multi-coloured fluorescence and chemiluminescence DNA and proteins exceeding forecast in Europe and strong sales in Europe and Asia of Synbiosis' ProtoCOL 3 system for automatically counting bacterial colonies also showing impressive growth.

Mike Creedon SDI's Chief Executive Officer, added: "The successful launch of Synoptics Health's ProReveal product is an example of SDI's repurposing our well-established technologies, and working with partners to develop new technologies for a previously untapped market sector. We believe the outlook for ProReveal in 2013 is very positive and that we will deliver short and long term benefits for shareholders and customers."

FOR FURTHER INFORMATION

Scientific Digital Imaging plc                                                         01223 727144

Ken Ford, Chairman

Mike Creedon, Chief Executive Officer

www.scientificdigitalimaging.com

finnCap Ltd.                                                                                      020 7220 0500

Ed Frisby/ Rose Herbert (corporate finance)

Simon Starr (corporate broking)

Note to Editors

Scientific Digital Imaging plc

Scientific Digital Imaging plc (SDI) is focused on the application of digital imaging technology to the needs of the scientific and technology community. Its principal subsidiary is Synoptics Limited, which designs and manufactures special-purpose instruments for use mainly in the life sciences, supplying customers in the academic, research and health sectors. In addition under the Atik brand SDI designs and manufactures high-sensitivity cameras for both astronomical and life science applications.

 

END

 

 

PRLGGGQWPUPPGRG